Eliquis (apixaban)

Eliquis is a leading anticoagulant medication, commonly referred to as a blood thinner, used to reduce the risk of stroke and systemic embolism in patients. The brand was developed through a strategic global collaboration between two pharmaceutical giants: Bristol-Myers Squibb (BMS) and Pfizer. Due to this partnership, the drug is manufactured in various high-tech pharmaceutical facilities across the globe, including significant production sites in Ireland and the United States.

The brand is co-owned and co-marketed by Bristol-Myers Squibb and Pfizer under the Bristol-Myers Squibb Pfizer Alliance. This joint venture allows both companies to leverage their combined research and distribution capabilities to maintain Eliquis as a primary treatment in the cardiovascular market. While BMS serves as the lead company in primary clinical development, both companies share the commercial benefits and operational responsibilities globally.